Publications

5674 Results

Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Authors
P Ganz;R Cecchini;T Julian;R Margolese;J Costantino;J Vallow;K Albain;P Whitworth;M Cianfrocca;A Brufsky;H Gross;G Soori;J Hopkins;L Fehrenbacher;K Sturtz;T Wozniak;TE Seay;E Mamounas;N Wolmark
Journal / Conference
Lancet, Feb 27;387(10021):857-865
Year
2016
Research Committee(s)
Breast
PMID
PMID26686960
PMC
PMC4792658

Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial

Authors
R Margolese;R Cecchini;T Julian;P Ganz;J Costantino;L Vallow;K Albain;P Whitworth;M Cianfrocca;A Brufsky;H Gross;G Soori;J Hopkins;L Fehrenbacher;K Sturtz;T Wozniak;TE Seay;E Mamounas;N Womark
Journal / Conference
Lancet Feb 27;387(10021):849-856
Year
2016
Research Committee(s)
Breast
PMID
PMID26686957
PMC
PMC4792688

The 21-gene recurrence score and locoregional recurrence rates in patients with node-positive breast cancer treated on SWOG S8814

Authors
W Woodward;W Barlow;R Jagsi;T Buccholz;S Shak;F Baehner;C Yoshizawa;T Whelan;N Davidson;J Ingle;T King;P Ravdin;C Osborne;D Tripathy;R Livingston;J Gralow;G Hortobagyi;D Hayes;K Albain
Journal / Conference
Int J Radiat Oncol Biol Phys. 2016 Oct 1;96(2S):S146;oral; ASTRO Annal Meeting (September 25 - 28, 2016, Boston, MA)
Year
2016
Research Committee(s)
Breast
Study Number(s)
SWOG-8814

Effect of measurable ("minimal") residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia

Authors
M Othus;B Wood;D Stirewalt;E Estey;S Petersdorf;F Appelbaum;H Erba;R Walter
Journal / Conference
Leukemia Oct;30(10):2080-2083; 2016 May 2 [Epub ahead of print]
Year
2016
Research Committee(s)
Leukemia
PMID
PMID27133827
PMC
PMC5053842
Study Number(s)
S0106

Adjuvant therapy for high-risk kidney cancer: ECOG-ACRIN E2805

Authors
NB Haas;J Manola;R Uzzo;K Flaherty;C Wood;C Kane;M Jewett;J Dutcher;MB Atkins;M Pins;G Wilding;D Cella;L Wagner;S Matin;T Kuzel;W Sexton;Y Wong;T Choueiri;R Pili;R Puzanov;M Kohli;W Stadler;M Carducci;R Coomes;R Dipaola
Journal / Conference
Lancet May 14;387(10032):2008-2016; 2016 Mar 8 [Epub ahead of print]
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID26969090
PMC
PMC4878938
Study Number(s)
CTSU/E2805

SWOG S0800 (NCI CDR0000636131):Addition of bevacizumab to neoadjuvant nab-paclitaxel with dose–dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancer

Authors
Z Nahleh;W Barlow;D Hayes;A Schott;J Gralow;E Perez;W Sikov;S Chennuru;H Mirshahidi;S Corso;D Lew;L Pusztai;R Livingston;G Hortobagyi
Journal / Conference
Breast Cancer Research and Treatment Aug;158(3):485-495; 2016 Jul 8 [Epub ahead of print]
Year
2016
Research Committee(s)
Breast
PMID
PMID27393622
PMC
PMC4963434
Study Number(s)
S0800

Phase II studies of two different schedules of dasatinib in bone-metastasis predominant metastatic breast cancer: SWOG S0622

Authors
A Schott;W Barlow;C Van Poznak;D Hayes;C Moinpour;D Lew;C Reynolds;P Dy;E Keller;J Keller;G Hortobagyi
Journal / Conference
Breast Cancer Research and Treatment Aug;159(1):87-95; 2016 Jul 30 [Epub ahead of print]
Year
2016
Research Committee(s)
Breast
PMID
PMID27475087
PMC
PMC5021222
Study Number(s)
S0622

Molecular heterogeneity and response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib

Authors
LA Carey;DA Berry;CT Cirrincione;WT Barry;BN Pitcher;LN Harris;DW Ollila;IE Krop;NL Henry;DJ Weckstein;CK Anders;B Singh;KA Hoadley;M Iglesia;M Cheang;C Perou;E Winer;C Hudis
Journal / Conference
Journal of Clinical Oncology, Feb 20;34(6):542-549
Year
2016
Research Committee(s)
Breast
PMID
PMID26527775
PMC
PMC4980567

Patterns of local-regional management following neoadjuvant chemotherapy in breast cancer: results from ACOSOG Z1071 (Alliance)

Authors
BG Haffty;LM McCall;KV Ballman;S McLaughlin;R Jagsi;DW Ollila;KS Hunt;TA Buchholz
Journal / Conference
International Journal of Radiation Oncology, Biology & Physics, Mar 94(3):493-502
Year
2016
Research Committee(s)
Breast
PMID
PMID26867878
PMC
PMC4752720

Identifying severe adverse event clusters using the National Cancer Institute's Common Terminology Criteria for Adverse Events

Authors
X Zhong;E Lim;DL Hershman;CM Moinpour;JM Unger;SM Lee
Journal / Conference
Journal of Oncology Practice, Mar;12(3):245-246
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID26907453
PMC
PMC5702793
Study Number(s)
S9916